India to Poland: Regorafenib Export Trade Route
India has recorded 15 verified shipments of Regorafenib exported to Poland, representing a combined trade value of $8.8K USD. This corridor is served by 6 active Indian exporters, with an average shipment value of $588 USD. The leading Indian exporter is LEOWIN HEALTHCARE LLP, which accounts for 40% of total export value with 9 shipments worth $3.5K USD. On the buying side, PEKAO-CARGO SPOLKA Z O.O is the largest importer in Poland with $2.8K USD in purchases. The top 3 suppliers — LEOWIN HEALTHCARE LLP, VINAYAK ASSOCIATES , SACRED LEAVES PRIVATE LIMITED — together control 84% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to Poland Regorafenib corridor is one of India's established pharmaceutical export routes, with 15 shipments documented worth a combined $8.8K USD. The route is dominated by LEOWIN HEALTHCARE LLP, which alone accounts for roughly 40% of all export value, reflecting the consolidated nature of India's regorafenib manufacturing sector.
Across 6 active suppliers, the average shipment value stands at $588 USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 80% of all shipments, consistent with regorafenib's non-urgent bulk-order profile.
Shipment activity peaks during April–June, with an average transit time of 26 days port-to-port. The route has recorded an annual growth rate of 12.6%, placing it at rank #17 among India's top regorafenib export destinations globally.
On the import side, key buyers of Indian regorafenib in Poland include PEKAO-CARGO SPOLKA Z O.O , TO THE ORDER.., TO THE ORDER and 5 others. PEKAO-CARGO SPOLKA Z O.O is the single largest importer with 2 shipments valued at $2.8K USD.
